Innovative Product Launch Orasis Pharmaceuticals recently launched Qlosi, a novel eye drop for presbyopia, creating a significant market opportunity for healthcare providers, pharmacies, and eye care specialists seeking advanced treatment options for age-related vision issues.

Strong Funding Support With a recent Series D financing of $78 million and additional structured capital of $15 million, Orasis is well-funded to expand distribution channels, invest in marketing efforts, and build strategic partnerships to accelerate product adoption.

Leadership Expansion Key leadership appointments in sales, quality, and operations indicate a focus on scaling commercial efforts and ensuring high-quality product delivery, presenting opportunities to collaborate on supply chain management, training programs, and sales strategies.

Market Focus on Presbyopia As the company concentrates on reformulated eye drops for presbyopia, there is potential to develop targeted outreach programs to optometrists, ophthalmologists, and clinics specializing in age-related eye care.

Digital Ecosystem Readiness Utilizing a diverse technology stack and online presence, Orasis is positioned to leverage digital marketing, telehealth integrations, and electronic health record systems to enhance product awareness and streamline sales channels.